利妥昔单抗与硫唑嘌呤治疗MOG抗体相关疾病（MOGAD）疗效比较

IF 2.5 4区医学 Q3 IMMUNOLOGY

Journal of neuroimmunology Pub Date : 2025-07-09 DOI:10.1016/j.jneuroim.2025.578686

Sedat Şen , Murat Kürtüncü , Serkan Demir , Tuncay Gündüz , Ezgi Demirel , Melih Tütüncü , Cihat Uzunköprü , Damla Cetinkaya Tezer , Ferah Kızılay , Belgin Petek Balcı , Gökhan Arslan , Caner Feyzi Demir , Nazire Pınar Acar Özen , Yeşim Beckmann , İpek Güngör Doğan , Uğur Uygunoğlu , Serkan Özakbaş , Mesrure Köseoğlu , Haluk Gümüş , Nuray Bilge , Aslı Tuncer

{"title":"利妥昔单抗与硫唑嘌呤治疗MOG抗体相关疾病（MOGAD）疗效比较","authors":"Sedat Şen , Murat Kürtüncü , Serkan Demir , Tuncay Gündüz , Ezgi Demirel , Melih Tütüncü , Cihat Uzunköprü , Damla Cetinkaya Tezer , Ferah Kızılay , Belgin Petek Balcı , Gökhan Arslan , Caner Feyzi Demir , Nazire Pınar Acar Özen , Yeşim Beckmann , İpek Güngör Doğan , Uğur Uygunoğlu , Serkan Özakbaş , Mesrure Köseoğlu , Haluk Gümüş , Nuray Bilge , Aslı Tuncer","doi":"10.1016/j.jneuroim.2025.578686","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Azathioprine (AZA) and rituximab (RTX) are frequently used drugs in the treatment of Myelin Oligodendrocyte Glycoprotein Associated Disease (MOGAD).</div></div><div><h3>Objectives</h3><div>The aim of this study was to evaluate the efficacy and safety data of AZA and RTX treatments in MOGAD.</div></div><div><h3>Methods</h3><div>Patients diagnosed according to the 2023 MOGAD diagnostic criteria and receiving AZA or RTX treatment were included in the study.</div></div><div><h3>Results</h3><div>In 142 patients included in the study, the female/male value was 1.2. The rate of OCB positivity in MOGAD patients was 22.6 %. Patients on RTX had higher EDSS values than patients on AZA. However, the RTX group demonstrated a more pronounced improvement in disability, reflected by a greater negative trend in the ΔEDSS values. The attack-free rate was 78 % in the RTX group and 68 % in the AZA group during their treatment period. Both groups had no difference in the time of the first attack. The main factor affecting the time to first attack was having a higher EDSS at the time of treatment initiation. The survival analysis found that EDSS scores improved significantly in patients treated with RTX.</div></div><div><h3>Conclusion</h3><div>Although survival analyses for both treatments appear to be similar, using RTX provides better EDSS scores.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"407 ","pages":"Article 578686"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)\",\"authors\":\"Sedat Şen , Murat Kürtüncü , Serkan Demir , Tuncay Gündüz , Ezgi Demirel , Melih Tütüncü , Cihat Uzunköprü , Damla Cetinkaya Tezer , Ferah Kızılay , Belgin Petek Balcı , Gökhan Arslan , Caner Feyzi Demir , Nazire Pınar Acar Özen , Yeşim Beckmann , İpek Güngör Doğan , Uğur Uygunoğlu , Serkan Özakbaş , Mesrure Köseoğlu , Haluk Gümüş , Nuray Bilge , Aslı Tuncer\",\"doi\":\"10.1016/j.jneuroim.2025.578686\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Azathioprine (AZA) and rituximab (RTX) are frequently used drugs in the treatment of Myelin Oligodendrocyte Glycoprotein Associated Disease (MOGAD).</div></div><div><h3>Objectives</h3><div>The aim of this study was to evaluate the efficacy and safety data of AZA and RTX treatments in MOGAD.</div></div><div><h3>Methods</h3><div>Patients diagnosed according to the 2023 MOGAD diagnostic criteria and receiving AZA or RTX treatment were included in the study.</div></div><div><h3>Results</h3><div>In 142 patients included in the study, the female/male value was 1.2. The rate of OCB positivity in MOGAD patients was 22.6 %. Patients on RTX had higher EDSS values than patients on AZA. However, the RTX group demonstrated a more pronounced improvement in disability, reflected by a greater negative trend in the ΔEDSS values. The attack-free rate was 78 % in the RTX group and 68 % in the AZA group during their treatment period. Both groups had no difference in the time of the first attack. The main factor affecting the time to first attack was having a higher EDSS at the time of treatment initiation. The survival analysis found that EDSS scores improved significantly in patients treated with RTX.</div></div><div><h3>Conclusion</h3><div>Although survival analyses for both treatments appear to be similar, using RTX provides better EDSS scores.</div></div>\",\"PeriodicalId\":16671,\"journal\":{\"name\":\"Journal of neuroimmunology\",\"volume\":\"407 \",\"pages\":\"Article 578686\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of neuroimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0165572825001675\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572825001675","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

硫唑嘌呤（AZA）和利妥昔单抗（RTX）是治疗髓鞘少突胶质细胞糖蛋白相关疾病（MOGAD）的常用药物。目的评价AZA和RTX治疗MOGAD的疗效和安全性。方法入选符合2023年MOGAD诊断标准并接受AZA或RTX治疗的患者。结果纳入研究的142例患者中，男女比值为1.2。MOGAD患者OCB阳性率为22.6%。RTX组患者的EDSS值高于AZA组。然而，RTX组在残疾方面表现出更明显的改善，反映在ΔEDSS值的更大的负趋势上。RTX组和AZA组在治疗期间无发作率分别为78%和68%。两组在第一次攻击的时间上没有差异。影响首次发作时间的主要因素是治疗开始时EDSS较高。生存分析发现，接受RTX治疗的患者的EDSS评分显著提高。尽管两种治疗的生存分析似乎相似，但RTX提供了更好的EDSS评分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)

Background

Azathioprine (AZA) and rituximab (RTX) are frequently used drugs in the treatment of Myelin Oligodendrocyte Glycoprotein Associated Disease (MOGAD).

Objectives

The aim of this study was to evaluate the efficacy and safety data of AZA and RTX treatments in MOGAD.

Methods

Patients diagnosed according to the 2023 MOGAD diagnostic criteria and receiving AZA or RTX treatment were included in the study.

Results

In 142 patients included in the study, the female/male value was 1.2. The rate of OCB positivity in MOGAD patients was 22.6 %. Patients on RTX had higher EDSS values than patients on AZA. However, the RTX group demonstrated a more pronounced improvement in disability, reflected by a greater negative trend in the ΔEDSS values. The attack-free rate was 78 % in the RTX group and 68 % in the AZA group during their treatment period. Both groups had no difference in the time of the first attack. The main factor affecting the time to first attack was having a higher EDSS at the time of treatment initiation. The survival analysis found that EDSS scores improved significantly in patients treated with RTX.

Conclusion

Although survival analyses for both treatments appear to be similar, using RTX provides better EDSS scores.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of neuroimmunology 医学-免疫学

CiteScore

6.10

自引率

3.00%

发文量

154

审稿时长

37 days

期刊介绍： The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.